Valuation : Supernus Pharmaceuticals, Inc.

Market Cap 256.86Cr 220.49Cr 206.43Cr 189.02Cr 356.08Cr 25TCr 357.09Cr 2.44TCr 955.56Cr 12TCr 964.39Cr 943.56Cr 41TCr P/E 2026 *
-221x
P/E 2027 * 36x
Enterprise Value 256.86Cr 220.49Cr 206.43Cr 189.02Cr 356.08Cr 25TCr 357.09Cr 2.44TCr 955.56Cr 12TCr 964.39Cr 943.56Cr 41TCr EV / Sales 2026 *
2.9x
EV / Sales 2027 * 1.87x
Free-Float
95.51%
Yield 2026 *
-
Yield 2027 * -
1 day-1.54%
1 week-6.87%
Current month-0.99%
1 month-5.94%
3 months-5.25%
6 months-19.26%
Current year-11.09%
1 week 43.89
Extreme 43.89
45.86
1 month 42.62
Extreme 42.625
52.5
Current year 42.45
Extreme 42.45
59.68
1 year 42.45
Extreme 42.45
59.68
3 years 21.99
Extreme 21.99
59.68
5 years 21.99
Extreme 21.99
59.68
10 years 13.12
Extreme 13.12
61.25
Manager TitleAgeSince
Chief Executive Officer 64 22/12/2005
Director of Finance/CFO 67 23/08/2021
Compliance Officer 63 01/01/2012
Director TitleAgeSince
Director/Board Member 64 22/12/2005
Chairman 81 10/08/2016
Director/Board Member 80 16/11/2010
Date Insider Type Main position Quantity % Market Cap.
12/08/26 Fiscal year

Chief Technology Officer

4,097 0.0073%
12/08/26 Fiscal year

Chief Financial Officer

3,104 0.0055%
12/08/26 Fiscal year

Founder

72,340 0.1290%
Change 5-day change 1-year change 3-year change Capi.($)
-1.54%-6.87%-1.95%+40.78% 256.86Cr
-2.33%+0.37%+77.88%+35.69% 37TCr
+1.05%+1.48%+29.60%-12.60% 7.1TCr
-0.13%+0.75%+46.11%+150.46% 1.21TCr
+1.62%+2.80%+3.74%+1.04% 860.44Cr
-2.31%-0.94%-16.02%-0.35% 498.8Cr
-1.19%+4.65%-28.68%+15.69% 446.46Cr
+1.34%-11.74%-32.42%+8.76% 322.19Cr
+2.75%-4.05%-15.05%-3.95% 219.51Cr
+0.08%+4.61%+262.67%+1,186.86% 179.13Cr
Average +0.07%-0.15%+32.59%+142.24% 4.8TCr
Weighted average by Cap. -0.01%+0.50%+65.73%+34.23%

Financials

2026 *2027 *
Net sales 89Cr 76Cr 71Cr 65Cr 122.8Cr 8.46TCr 123.14Cr 842.96Cr 329.53Cr 4.26TCr 332.57Cr 325.39Cr 14TCr 137.16Cr 117.74Cr 110.23Cr 100.94Cr 190.15Cr 13TCr 190.68Cr 1.31TCr 510.26Cr 6.6TCr 514.98Cr 503.86Cr 22TCr
Net income -1.15Cr -99.09L -92.77L -84.95L -1.6Cr -110.26Cr -1.6Cr -11Cr -4.29Cr -56Cr -4.33Cr -4.24Cr -183.91Cr 7.15Cr 6.14Cr 5.75Cr 5.26Cr 9.92Cr 683.28Cr 9.95Cr 68Cr 27Cr 344.37Cr 27Cr 26Cr 1.14TCr
Net Debt - -
Logo Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Employees
778
Date Price Change Volume
27/26/27 $44.19 -1.54% 4,64,947
26/26/26 $44.88 -1.06% 4,99,684
25/26/25 $45.36 +0.55% 4,96,056
24/26/24 $45.11 -1.61% 4,95,505
21/26/21 $45.85 -3.37% 7,48,894
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
44.19USD
Average target price
61.75USD
Spread / Average Target
+39.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SUPN Stock